Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPF
Vanessa Welk, Shane A. Olwill(Pieris Pharmaceuticals (United States)), Janet K. Peper-Gabriel, Gabriele Matschiner(Pieris Pharmaceuticals (United States)), Eva-Maria Hansbauer(Pieris Pharmaceuticals (United States)), Thomas J. Jaquin(Pieris Pharmaceuticals (United States)), Antonio Konitsiotis(Pieris Pharmaceuticals (United States)), Stefan Grüner, Josefine Morgenstern, Claudia Wurzenberger(Pieris Pharmaceuticals (United States)), Cornelia Wurzenberger(Pieris Pharmaceuticals (United States)), Josef Prassler, Marina Pavlidou(Pieris Pharmaceuticals (United States))
Cited by 3
Related Papers
The phosphopantetheinyl transferase KirP activates the ACP and PCP domains of the kirromycin NRPS/PKS of Streptomyces collinus Tü 365
|FEMS Microbiology Letters|2011|24
Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment
|Nature Communications|2025|13
Abstract LB220: The anticalin-antibody bispecific PRS-352/S095025 strongly stimulates human CD4+ T cells in a PD-L1-dependent manner
|Cancer Research|2022|2